| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine (W.L.S.-P., A.R.) and Surgery (J.R.T.L.), University of Alberta, Edmonton, Canada T6G 2S2; and Waratah Pharmaceuticals (S.J.B.), Woburn, Massachusetts 01801
Address all correspondence and requests for reprints to: Dr. Alex Rabinovitch, 430 Heritage Medical Research Center, University of Alberta, Edmonton, Alberta, Canada T6G 2S2. E-mail: alex.rabinovitch{at}ualberta.ca.
Pancreatic islet transplantation is a viable treatment for type 1 diabetes, but is limited by human donor tissue availability. The combination of epidermal growth factor (EGF) and gastrin induces islet ß-cell neogenesis from pancreatic exocrine duct cells in rodents. In this study we investigated whether EGF and gastrin could expand the ß-cell mass in adult human isolated islets that contain duct as well as endocrine cells. Human islet cells were cultured for 4 wk in serum-free medium (control) or in medium with EGF (0.3 µg/ml), gastrin (1.0 µg/ml), or the combination of EGF and gastrin. ß-Cell numbers were increased in cultures with EGF plus gastrin (+118%) and with EGF (+81%), but not in cultures with gastrin (3%) or control medium (62%). After withdrawal of EGF and gastrin and an additional 4 wk in control medium, ß-cell numbers continued to increase only in cultures previously incubated with both EGF and gastrin (+232%). EGF plus gastrin also significantly increased cytokeratin 19-positive duct cells (+678%) in the cultures. Gastrin, alone or in combination with EGF, but not EGF alone, increased the expression of pancreatic and duodenal homeobox factor-1 as well as insulin and C peptide in the cytokeratin 19-positive duct cells. Also, EGF plus gastrin significantly increased ß-cells and insulin content in human islets implanted in immunodeficient nonobese diabetic-severe combined immune deficiency mice as well as insulin secretory responses of the human islet grafts to glucose challenge. In conclusion, combination therapy with EGF and gastrin increases ß-cell mass in adult human pancreatic islets in vitro and in vivo, and this appears to result from the induction of ß-cell neogenesis from pancreatic exocrine duct cells.
This article has been cited by other articles:
![]() |
D. A. Taylor-Fishwick, A. Bowman, M. Korngiebel-Rosique, and A. I. Vinik Pancreatic Islet Immunoreactivity to the Reg Protein INGAP J. Histochem. Cytochem., February 1, 2008; 56(2): 183 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mussmann, M. Geese, F. Harder, S. Kegel, U. Andag, A. Lomow, U. Burk, D. Onichtchouk, C. Dohrmann, and M. Austen Inhibition of GSK3 Promotes Replication and Survival of Pancreatic Beta Cells J. Biol. Chem., April 20, 2007; 282(16): 12030 - 12037. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gianani The Multiple Endocrine Neoplasia Type-1 (MEN-1) Syndrome and Its Effect on the Pancreas J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 811 - 812. [Full Text] [PDF] |
||||
![]() |
K. Robertson, J. J. Kopchick, and J.-L. Liu Growth hormone receptor gene deficiency causes delayed insulin responsiveness in skeletal muscles without affecting compensatory islet cell overgrowth in obese mice Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E491 - E498. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Suarez-Pinzon, Y. Yan, R. Power, S. J. Brand, and A. Rabinovitch Combination Therapy With Epidermal Growth Factor and Gastrin Increases {beta}-Cell Mass and Reverses Hyperglycemia in Diabetic NOD Mice Diabetes, September 1, 2005; 54(9): 2596 - 2601. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |